Myriad Genetics, Inc.
MYGN
$3.05
-$0.15-4.69%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -4.84% | -4.48% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -4.84% | -4.48% | |||
| Cost of Revenue | 1.43% | -0.32% | |||
| Gross Profit | -7.70% | -6.27% | |||
| SG&A Expenses | 3.76% | 9.25% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.73% | 6.06% | |||
| Operating Income | -53.75% | -743.33% | |||
| Income Before Tax | -24.93% | -283.15% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -26.69% | -331.65% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -26.69% | -331.65% | |||
| EBIT | -53.75% | -743.33% | |||
| EBITDA | -106.25% | -233.33% | |||
| EPS Basic | -25.23% | -329.63% | |||
| Normalized Basic EPS | -46.76% | -361.20% | |||
| EPS Diluted | -26.41% | -329.63% | |||
| Normalized Diluted EPS | -46.76% | -361.20% | |||
| Average Basic Shares Outstanding | 1.17% | 0.43% | |||
| Average Diluted Shares Outstanding | 1.17% | 0.43% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||